for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

6,979.00GBp

Change

63.00(+0.91%)

Volume

2,545,454

Today's Range

6,903.00

 - 

7,000.00

52 Week Range

5,312.00

 - 

8,227.88

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
6,916.00
Open
6,915.00
Volume
2,545,454
3M AVG Volume
39.76
Today's High
7,000.00
Today's Low
6,903.00
52 Week High
8,227.88
52 Week Low
5,312.00
Shares Out (MIL)
1,311.89
Market Cap (MIL)
91,854.70
Forward P/E
24.11
Dividend (Yield %)
--

Next Event

Q3 2019 AstraZeneca PLC Earnings Release

Latest Developments

More

ImaginAb Signs Multi-Party Collaboration Agreement With 3 Global Pharmaceutical Cos

Astrazeneca Divests Rights For Losec To Cheplapharm

AstraZeneca Updates On US Regulatory Review Of PT010 In Copd

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

2.30 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

23.0K

2017

22.5K

2018

22.1K

2019(E)

23.8K
EPS (USD)

2016

4.310

2017

4.280

2018

3.460

2019(E)

3.595
Price To Earnings (TTM)
51.23
Price To Sales (TTM)
5.02
Price To Book (MRQ)
8.55
Price To Cash Flow (TTM)
19.80
Total Debt To Equity (MRQ)
145.44
LT Debt To Equity (MRQ)
131.89
Return on Investment (TTM)
4.80
Return on Equity (TTM)
3.38

Latest News

Latest News

FDA green lights AstraZeneca's asthma drug Fasenra for self-administration

British drugmaker AstraZeneca said on Friday that the U.S. Food and Drug Administration (FDA) has approved self-administration of its asthma treatment Fasenra which uses a pre-filled, single-use auto-injector pen.

AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm

AstraZeneca Plc said on Tuesday it would sell the global commercial rights for its drug to treat acid reflux to German pharmaceutical company Cheplapharm Arzneimittel GmbH for as much as $276 million.

AstraZeneca's combo lung disease therapy fails to win FDA approval

The U.S. Food and Drug Administration declined to approve AstraZeneca Plc's <AZN.L> combination therapy to treat smoker's lung, the drugmaker said on Tuesday.

AstraZeneca's combo lung disease therapy falls short of FDA approval

The U.S. Food and Drug Administration declined to approve AstraZeneca Plc's combo therapy to treat a form of lung disease, the drugmaker said on Tuesday.

AstraZeneca strengthens Lynparza push with prostate cancer data

AstraZeneca presented results on Monday for a trial of its Lynparza drug against prostate cancer, which it hopes could lead to wider regulatory approval for the treatment for use against more forms of the disease.

AstraZeneca, Merck ovarian cancer treatment improves progression-free survival

AstraZeneca Plc and Merck & Co Inc said on Monday their treatment for newly diagnosed advanced ovarian

AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival

AstraZeneca Plc and Merck & Co Inc said on Monday their drug to treat a form of ovarian cancer improved progression-free survival in patients tested in a late-stage study.

FTSE gains as Thomas Cook collapse buoys blue-chip rivals

London's FTSE 100 index inched higher on Monday, helped by gains for several rival tour operators and airlines after the collapse of Thomas Cook and positive approvals news for drugmaker AstraZeneca.

AstraZeneca diabetes drug granted fast track status for heart failure treatment

AstraZeneca's diabetes drug, Farxiga, has been granted fast track designation by U.S. regulators for the treatment of heart failure, boosting prospects of wider use of the drug and putting it ahead of rivals.

AstraZeneca's Farxiga granted fast track status for heart failure treatment

AstraZeneca Plc said on Monday the U.S. Food and Drug Administration (FDA) had granted fast track designation for the development of its diabetes drug Farxiga to reduce the risk of deadly heart attacks in some patients.

AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer

AstraZeneca's cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs.

AstraZeneca's Tagrisso helps lung cancer patients live longer: study

(Corrects Aug. 9 story to show study points to overall survival and not progression free survival in first paragraph)

CORRECTED-UPDATE 1-AstraZeneca's Tagrisso helps lung cancer patients live longer- study (Aug. 9)

AstraZeneca Plc said on Friday a late-stage study showed its top-selling drug, Tagrisso, had significantly helped patients with a type of lung cancer live longer.

AstraZeneca's Tagrisso gets China OK for type of lung cancer

AstraZeneca Plc <AZN.L> said on Wednesday it had received marketing authorisation from China's National Medical Products Administration for its top-selling drug, Tagrisso, to treat adults with a form of lung cancer.

AstraZeneca lupus drug shows promise after set-back last year

AstraZeneca Plc said on Thursday its experimental drug to treat moderate-to-severe lupus met the main goal in a late-stage study, an encouraging sign after it failed to meet its main target in the final stage of another trial last year.

AstraZeneca lupus drug meets main goal in study

AstraZeneca Plc said on Thursday its experimental drug to treat moderate-to-severe lupus, anifrolumab, met its main goal in a late-stage study.

AstraZeneca respiratory business gets boost from three-drug inhaler results

Prospects for AstraZeneca's <AZN.L> respiratory treatments business improved on Wednesday as a three-drug inhaler was shown to ease smoker's lung and U.S. regulators granted its injectable asthma drug Fasenra special status for a rare lung condition.

U.S. FDA grants orphan drug status to AstraZeneca's asthma drug Fasenra

AstraZeneca said on Wednesday that the U.S. Food and Drug Administration has granted orphan drug status to its severe asthma drug, Fasenra, to treat eosinophilic oesophagitis (EoE).

FDA gives fast track status to AstraZeneca's diabetes drug Farxiga

AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration has granted fast track status for the development of its diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease (CKD).

AstraZeneca says U.S. FDA grants fast track status for diabetes drug Farxiga

AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration granted fast track status for the development of its diabetes drug Farxiga to prevent heart and kidney failure in patients with long-term kidney disease.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up